



University of  
**Sheffield**

# **Bespoke structured expert elicitation protocol for long-term survival outcomes**

*NICE DSU TSD 26*

**Kate Ren**

Sheffield Centre for Health and Related Research (SCHARR)

University of Sheffield

09.06.2025

## Disclaimer

- This study is funded by the National Institute for Health and Care Excellence (NICE) Decision Support Unit (DSU).
- Employed (part-time) by the University of Sheffield
- Employed (part-time) by ConnectHEOR
- Member of NICE Technology Appraisal Committee C

# Why is a bespoke protocol needed for time-to-event data?

## 1 Critical role in determining cost-effectiveness

- Extrapolated survival outcomes can have large variability resulting in uncertain incremental cost-effectiveness ratios


## 2 Uniqueness of time-to-event data

- Censoring
- Underlying hazard function


## 3 Need an approach which ensures consistency with qualitative knowledge

- Meaningful representation of the elicited values given the qualitative knowledge

### NICE TA621: Osimertinib for untreated EGFR-positive non-small-cell lung cancer



# NICE TSD 26: Expert Elicitation for Long-Term Survival Outcomes



**TECHNICAL SUPPORT DOCUMENT 26:**  
EXPERT ELICITATION FOR LONG-TERM  
SURVIVAL OUTCOMES




**Structured Expert Elicitation**

**TECHNICAL SUPPORT DOCUMENT 14:**  
SURVIVAL ANALYSIS FOR ECONOMIC  
EVALUATIONS ALONGSIDE CLINICAL  
TRIALS-EXTRAPOLATION WITH PATIENT  
LEVEL DATA



**TECHNICAL SUPPORT DOCUMENT 21:**  
FLEXIBLE METHODS FOR SURVIVAL  
ANALYSIS



## OUTPUTS

- **Probability distribution** quantifying expert uncertainty
- **Qualitative opinion** about how the hazard may change

## HOW



**Bespoke protocol** integrating survival and hazard judgements

**Evidence dossier** summarising relevant information to support the experts when making judgements




**Training** of experts in making probability judgements; survivor and hazard functions; practice elicitation exercise

**Panel** of experts, individual elicitation; qualitative and quantitative assessments; scenario testing; aggregation



**Reporting** for full transparency, including the expert recruitment process; hazard discussion; individual and aggregated judgements


# NICE TSD 26: bespoke SEE protocol adapted from SHELF



# NICE STA ID1441: tebentafusp for advanced uveal melanoma

- 1 Two appraisal committee meetings
- 2 Tebentafusp was not recommended
- 3 Appeal hearing with upheld points

*“it is the panel's view that reasonableness requires they should **seek additional expert clinical input** on areas of important residual uncertainty, notably the most appropriate choice, and interpretation of **survival curve models** to interrogate the available data, and the most appropriate means of allocating supportive care costs in the model.”*



## NICE DSU was instructed to




Use a structured approach to elicit expert estimates of the expected survival of people with uveal melanoma treated with pembrolizumab and those treated with tebentafusp and the uncertainty around these estimates



Also consider how the learnings from this exercise might inform the use of expert elicitation in future appraisals



# NICE STA ID1441: structured expert elicitation




# Obtaining individual expert judgements


- Guidance: SHELF protocol
- Quartile method (variable interval approach)
  - Lower and upper plausible limits
  - Median
  - Lower quartile (Q1)
  - Upper quartile (Q3)
- No discussion between experts
- Experts can clarify with the facilitator

## Individual judgements

Tebentafusp





Pembrolizumab





# The hazard function

- Related to ‘instantaneous risk of death’ at time  $t$  for a patient who has survived up to time  $t$
- Corresponds to trend in survivor function



# Group discussion: Obtaining qualitative opinion on hazard trend



To identify whether expert believes the hazard in the target population to be changing with time and why



## Increasing hazard

- **Disease**
  - Continuous deterioration
  - Aggressive disease
- **Patient group**
  - Advancing age
  - Trial inclusion/exclusion criteria
- **Treatment**
  - Not controlling the disease well
  - Delayed treatment effect



## Decreasing hazard

- **Disease**
  - Improving naturally
- **Patient group**
  - Presence of subgroups within the population
- **Treatment**
  - Improvement of condition greater than deterioration due to disease
  - Cure

# Scenario testing

## Aim: to give a point of reference for reflection on expert's individual judgements

Note: no claims were made by the elicitation team regarding the probability of the scenario being true.


### Procedure

After individual judgements, the experts were presented with an extrapolation based on a particular scenario

An approx. 95% credible interval reported indicative of a **range of values statistically consistent** with the assumption of **no change in the hazard**

Experts are invited to reflect on whether their plausible ranges exceeded either interval limit


Provide a starting point for the group discussion



- An exponential model was fitted to month 100-150 survival data and extrapolated to month 250
- Scenario where hazard remains unchanged from month 100 to 250

# Individual judgements and scenario testing: tebentafusp arm

- Experts provide upper and lower plausible limits, median and upper and lower quartiles



→ **Upper Kaplan-Meier  
97.5% confidence limit  
for survival at 4 years**

→ **Scenario testing**

# Elicited distributions

## Elicited quantities for each arm



### Tebentafusp

- 10% probability that survival is less than 50 per 1000
- 50% probability that survival is greater than 100 per 1000
- 5% probability that survival is greater than 150 per 1000


### Pembrolizumab

As there was little disagreement between the experts, the Facilitator proposed assuming initial RIO judgements to be the median and quartiles computed as averages of the experts' individual judgements

## Fitted distribution for each arm



## Fitted distribution for each arm



# Our observations from NICE STA ID1441 case study

## Expert recruitment

- Stakeholder involvement
- Initial email with motivations
- Follow-ups

## Experts' normative skills

- Interactive training
- Include training on survival and hazard
- Practice exercise

## Quantity of interest

- Two quantities
- Precise definition
- Health economist input

## Evidence dossier

- Literature review
- Expert review prior to workshop

## Workshop format

- Online is as effective as F2F

## Resources required

- 3 months
- Evidence dossier and expert recruitment preparation most time consuming

## Constraints of HCDM

- Overwhelmingly positive response from the clinical community
- Travel and accommodation were reimbursed

## Heuristics and biases

- Overconfidence, anchoring and availability biases managed via facilitation

# Summary and key recommendations from TSD 26

- 1 Relationship between survivor and hazard function
  - Elicited values should have internal consistency between the qualitative knowledge and quantitative estimate
  - Scenario testing
  - Qualitative discussion
- 2 Interaction between experts
  - Ensure commitment
  - Help expert understanding
  - Validate judgements
- 3 Accurate and thorough reporting of the quantitative and qualitative aspects of the elicitation ensures maximum usefulness of the workshop outputs

**Plan in advance!**



# References

- Oakley J. E., Ren S., Forsyth J. E., Gosling J. P., Wilson K., Latimer N., Rutherford M. J., Uttley L., Fotheringham J., NICE DSU Technical Support Document 26: Expert elicitation for long-term survival outcomes. 2025. Available from <http://www.nicedsu.org.uk>
- Oakley JE, O'Hagan A. SHELF: the Sheffield Elicitation Framework (version 4). <https://shelf.sites.sheffield.ac.uk>
- Software and training material for eliciting long-term survival: <https://shelf.sites.sheffield.ac.uk/survival-extrapolation>
- NICE. Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma. Technology Appraisal ID1441. Available at <https://www.nice.org.uk/guidance/indevelopment/gid-ta10428>, 2024